Immunohistochemical somatostatin receptor expression in insulinomas.
immunohistochemistry
insulinoma
neuroendocrine tumour
pathology of tumours
somatostatin receptors
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
06
01
2023
accepted:
19
01
2023
pubmed:
22
1
2023
medline:
14
3
2023
entrez:
21
1
2023
Statut:
ppublish
Résumé
Insulinomas are rare pancreatic neuroendocrine tumours. Most patients can be cured with surgery, but patients with a metastatic disease show impaired survival. The aim of this study was to evaluate somatostatin receptor (SSTR) 1-5 expression in insulinomas and to correlate the expression profile with clinicopathological variables and with patient outcome. This retrospective study involved 52 insulinoma patients. After histological re-evaluation, formalin-fixed paraffin-embedded tissue samples were processed into tissue microarrays and stained immunohistochemically with monoclonal SSTR1-5 antibodies. All the 52 tumours (49 non-metastatic, 3 metastatic) expressed at least one SSTR subtype. SSTR2 was expressed most frequently (71%), followed by SSTR3 (33%), SSTR1 (27%), SSTR5 (6%) and SSTR4 (0%). SSTR3 expression was associated with a larger tumour size (median diameter 19 mm vs. 13 mm, p = 0.043), and SSTR3 and SSTR5 expression were associated with impaired overall survival [HR 3.532 (95% CI 1.106-11,277), p = 0.033, and HR 6.805 (95% CI 1.364-33.955), p = 0.019 respectively]. Most insulinomas express SSTR2, which may be utilized in diagnostic imaging, and in planning individualized treatment strategies for insulinoma patients. Further studies are needed to clarify the association between SSTR profile and overall survival.
Substances chimiques
Receptors, Somatostatin
0
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152-160Subventions
Organisme : Emil Aaltonen Foundation
Organisme : the Finnish Cancer Foundation
ID : AROLA WBS 4707973
Organisme : the Helsinki University Hospital Research Fund
ID : AROLA WBS 4708047
Organisme : the Medical Research Fund of Seinäjoki Central Hospital
Organisme : the Research Funding provided by Seinäjoki City, Tampere University and Tampere University Hospital
Organisme : Tampere University Hospital
Informations de copyright
© 2023 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
Références
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119. https://doi.org/10.1159/000335591
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2009;94:709-28. https://doi.org/10.1210/jc.2008-1410
Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L, Diener MK, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43:675-86. https://doi.org/10.1097/MPA.0000000000000110
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153-71. https://doi.org/10.1159/000443171
Veltroni A, Cosaro E, Spada F, Fazio N, Faggiano A, Colao A, et al. Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. Eur J Endocrinol. 2020;182:439-46. https://doi.org/10.1530/EJE-19-0989
del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and somatostatin receptors: from signaling to clinical applications in neuroendocrine neoplasms. Biomedicine. 2021;9:1810. https://doi.org/10.3390/biomedicines9121810
Priyadashini S, Allison DB, Chauhan A. Comprehensive assessment of somatostatin receptors in various neoplasms: a systematic review. Pharmaceutics. 2022;14:1394. https://doi.org/10.3390/pharmaceutics14071394
Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105:212-44. https://doi.org/10.1159/000471879
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105:295-309. https://doi.org/10.1159/000475526
Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, et al. Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy. Front Endocrinol. 2021;12:679000. https://doi.org/10.3389/fendo.2021.679000
Andreassen M, Ilett E, Wiese D, Slater EP, Klose M, Hansen CP, et al. Surgical management, preoperative tumor localization, and histopathology of 80 patients operated on for insulinoma. J Clin Endocrinol Metabol. 2019;104:6129-38. https://doi.org/10.1210/jc.2019-01204
Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol. 2007;18:79-85. https://doi.org/10.1007/s12022-007-0014-8
Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757-67. https://doi.org/10.1530/eje.1.01901
Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50:52-60. https://doi.org/10.1136/gut.50.1.52
Peltola E, Hannula P, Huhtala H, Metso S, Kiviniemi U, Vornanen M, et al. Characteristics and outcomes of 79 patients with an insulinoma: a Nationwide retrospective study in Finland. Int J Endocrinol. 2018;2018:1-10. https://doi.org/10.1155/2018/2059481
Peltola E, Hannula P, Huhtala H, Metso S, Sand J, Laukkarinen J, et al. Long-term morbidity and mortality in patients diagnosed with an insulinoma. Eur J Endocrinol. 2021;185:577-86.
Digestive System Tumours. WHO classification of Tumours (5th ed.). WHO classification of Tumours editorial board. Lyon: IARC Press; 2019 ISBN 978-92-832-4499-8.
Majala S, Vesterinen T, Seppänen H, Mustonen H, Sundström J, Schalin-Jäntti C, et al. Correlation of somatostatin receptor 1-5 expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and clinical outcome in a prospective cohort of pancreatic neuroendocrine neoplasms. Cancer. 2022;14:162. https://doi.org/10.3390/cancers14010162
Elston MS, Meyer-Rochow GY, Conaglen HM, Clarkson A, Clifton-Bligh RJ, Conaglen JV, et al. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. Hum Pathol. 2015;46:390-6. https://doi.org/10.1016/j.humpath.2014.11.012
Körner M, Waser B, Schonbrunn A, Perren A, Reubi JC. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for In vivo somatostatin receptor targeting. Am J Surg Pathol. 2012;36:242-52. https://doi.org/10.1097/PAS.0b013e31823d07f3
Vesterinen T, Säilä J, Blom S, Pennanen M, Leijon H, Arola J. Automated assessment of Ki-67 proliferation index in neuroendocrine tumors by deep learning. APMIS. 2022;130:11-20. https://doi.org/10.1111/apm.13190
Watanabe H, Ide R, Yamazaki Y, Fujishima F, Kasajima A, Yazdani S, et al. Quantitative digital image analysis of somatostatin receptor 2 immunohistochemistry in pancreatic neuroendocrine tumors. Med Mol Morphol. 2021;54:324-36. https://doi.org/10.1007/s00795-021-00294-6
Yu J, Cao F, Zhao X, Xie Q, Lu M, Li J, et al. Correlation and comparison of somatostatin receptor type 2 immunohistochemical scoring systems with 68Ga-DOTATATE positron emission tomography/computed tomography imaging in gastroenteropancreatic neuroendocrine neoplasms. Neuroendocrinology. 2022;112:358-69. https://doi.org/10.1159/000517530
Remes SM, Leijon HL, Vesterinen TJ, Arola JT, Haglund CH. Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias. J Histochem Cytochem. 2019;67:735-43. https://doi.org/10.1369/0022155419856900